33630-99-8

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-2-pyridinol is used as a pharmaceutical intermediate for the synthesis of various therapeutic agents. It plays a vital role in the preparation of benzothiazolyl hydroxyindolinylphenyl ureas, which are potent P2Y1 antagonists. These antagonists have potential applications in the treatment of various diseases, including inflammation and pain.
3-Amino-2-pyridinol is also used in the synthesis of functionalized pyrido[4,3-b][1,4]oxazine and imidazo[1,2-a]pyridine derivatives. These derivatives have potential applications in the development of new drugs with diverse therapeutic properties.
In the chemical synthesis process, 3-amino-2-pyridinol can react with ethyl 2-chloro-3-oxopropanoate to produce imidazo[1,2-a]pyridine derivatives or ethyl pyrido[4,3-b][1,4]oxazine-2-carboxylate, depending on the specific reaction conditions and starting materials used.
Overall, 3-Amino-2-pyridinol is a versatile compound with significant applications in the pharmaceutical industry, particularly in the development of new drugs and therapeutic agents. Its unique chemical properties and reactivity make it an essential component in the synthesis of various bioactive molecules.

InChI:InChI=1/C5H6N2O/c6-4-2-1-3-7-5(4)8/h1-3H,6H2,(H,7,8)

Upstream product

• 6332-56-5 2-hydroxy-3-nitropyridine 
• 165547-79-5 2-hydroxy-3-nitro-4-chloropyridine 
• 142-08-5 2-hydroxypyridin 
• 16867-04-2 dihydroxypyridine 
• 118767-92-3 oxazolo[5,4-b]pyridin-2(3H)-one 
• 15010-23-8 3-acetamidopyridine N-oxide 
• 6332-56-5 3-nitropyridone 
• 92138-35-7 6-chloro-3-nitro-1H-pyridin-2-one 
• 56-40-6 glycine 
• 1462-86-8 3-amino-pyridine-2-carboxylic acid 
• 4214-75-9 2-amino-3-nitropyridine 
• 142-08-5 2-Pyridone 
• 98786-86-8 5-bromo-2-hydroxy-3-aminopyridine 

Downstream Products

• 100047-65-2 N-(2-hydroxy-[3]pyridyl)-formamide 
• 91813-42-2 2-(2-methyl)oxazolo<5,4-b>pyridine 
• 76349-07-0 N-(2-hydroxypyridin-3-yl)acetamide 
• 121974-49-0 N-(2-hydroxy-[3]pyridyl)-diacetamide 
• 108018-07-1 N-(2-hydroxy-[3]pyridyl)-toluene-4-sulfonamide 
• 67967-11-7 1,7-naphthyridinyl-8(7H)-one 
• 23827-33-0 N-(2-hydroxy-[3]pyridyl)-benzamide 
• 88972-92-3 2,6-Di-tert-butyl-4-oxazolo[5,4-b]pyridin-2-yl-phenol 
• 67967-11-7 8-hydroxy-1,7-naphthyridine 
• 197229-63-3 (2-hydroxypyridin-3-yl)carbamic acid tert-butyl ester 
• 169205-99-6 oxazolo[5,4-b]pyridine-2(1H)-thione 
• 118767-92-3 oxazolo[5,4-b]pyridin-2(3H)-one 
• 118487-95-9 5-hydroxy-4-[(3,5-dimethoxyphenyl)ureylene]-7-methylthieno[2,3-c]pyridine 

Relevant academic research and scientific papers

Synthesis and photophysical properties of the products of the reaction of 5-methyl-7-phenyl[1,3]oxazolo[5,4-b]pyridin-2(1H)-one with amino acids

[Figure not available: see fulltext.] The reaction of amino acid esters with 7-phenyl[1,3]oxazolo[5,4-b]pyridin-2(1H)-one led to the derivatives of 3-(2-oxo-4-phenyl-1,2-dihydropyridin-3-yl)imidazolidine-2,4-diones and ethyl 2-[3-(2-oxo-4-phenyl-1,2-dihyd

Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: Design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues

The obligate intracellular bacterium Chlamydia trachomatis (C. trachomatis) is responsible for the most common bacterial sexually transmitted infection and is the leading cause of preventable blindness, representing a major global health burden. While C.

HMOX1 inducers

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

Synthesis and applications of 3-amino-2-hydroxypyridine

The invention discloses synthesis and applications of 3-amino-2-hydroxypyridine. The synthesis steps comprise: (1) dissolving 2-hydroxy-3-nitro-5-bromopyridine in a solvent, stirring, adding the mixture of iron powder and hydrochloric acid, carrying out a reaction for 0.5-1 h, and carrying out post-treatment to obtain 2-hydroxy-3-amino-5-bromopyridine; and (2) dissolving the 2-hydroxy-3-amino-5-bromopyridine obtained in the step (1) in an alkaline solution, adding strontium carbonate, introducing hydrogen into a reaction bottle, carrying out a reaction for a certain time, and carrying out conventional treatment to obtain 3-amino-2-hydroxypyridine. According to the present invention, the production cost is substantially reduced, and the obtained 3-amino-2-hydroxypyridine has the high purityand can be directly used in the next step.

A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS

A class of mono-protected 3-amino-2- hydroxypyridine (MPAHP) ligands that enable the meta- C-H arylation of anilines, phenols, phenylacetic acids, and biologically relevant heterocyclic compounds using norbornene as a transient mediator is disclosed. The applicability of this meta-arylation methodology in the pharmaceutical industry is illustrated for heteroaryl substrates and heteroaryl iodide coupling partners, a feat made possible by using the MPAHP ligand. The enabling nature of MPAHP ligands to achieve other meta-C-H functionalization processes is also illustrated by the development of a meta-C-H amination reaction and a meta-C-H alkynylation reaction.

Transformation of Streptonigrin to Streptonigrone: Flavin Reductase-Mediated Flavin-Catalyzed Concomitant Oxidative Decarboxylation of Picolinic Acid Derivatives

In the flavin-reductase-catalyzed reducing condition, a mild and efficient α-hydroxylation and decarboxylation procedure using natural flavins as a catalyst and atmospheric oxygen as an external oxidizing agent has been successfully developed and applied

HETEROCYCLIC DERIVATIVES

The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.

5-6-BICYCLIC HETEROAROMATIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors

The structure-based design, chemical synthesis and in vitro activity evaluation of various falcipain inhibitors derived from 2-pyridone are reported. These compounds contain a peptidomimetic binding determinant and a Michael acceptor terminal moiety capable of deactivating the cysteine protease active site.

3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES

The present invention relates to pyrid-2-one compounds of formula (I) useful as inhibitors of protein kinase of Tec family (e.g., Tec, Btk, Itk/Emt/Tsk, Bmx,Txk/Rlk) protein kinases. These compounds and pharmaceutically acceptable compositions thereof are